Evidence map›Paper›PMID 25475704›Full record

ReviewTrends in cell biology2015

Taming of the beast: shaping Myc-dependent amplification.

Elmar Wolf, Charles Y Lin, Martin Eilers, David L Levens

Open access · greenAbstract readReview
In one paragraph

Review in Trends in cell biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 136 citations in OpenAlex.

  1. Reactivation of the silencedProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Dynamic Supercoiling Sponsors Transcription Amplification by MYC.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. mInternational journal of oral science · 2024
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. MYC: a complex problem.Trends in cell biology · 2023
    Review
  20. Demystifying the Druggability of the MYC Family of Oncogenes.Journal of the American Chemical Society · 2023
    Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Elmar WolfTheodor Boveri Institute, Biocenter, and Comprehensive Cancer Center, University of Würzburg, Am Hubland, 97074 Würzburg, Germany.
Charles Y LinDepartment of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA. Electronic address: Charles_lin@dfci.harvard.edu.
Martin EilersTheodor Boveri Institute, Biocenter, and Comprehensive Cancer Center, University of Würzburg, Am Hubland, 97074 Würzburg, Germany. Electronic address: martin.eilers@biozentrum.uni-wuerzburg.de.
David L LevensLaboratory of Pathology, 10 Center Drive, Bethesda, MD 20892-1500, USA. Electronic address: levens@helix.nih.gov.
University of Würzburg · DEDana-Farber Cancer Institute · USNational Institutes of Health Clinical Center · US

Funding

c-Myc FunctionZIABC011465 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LEVENS, DAVID L. · 2012 to 2025
$8.6M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011465
6 · The paper itself

Abstract

Myc deregulation is a hallmark oncogenic event where overexpression of the transcription factor gives rise to numerous tumorigenic phenotypes. The complex consequences of Myc deregulation have prevented clear mechanistic interpretations of its function. A synthesis of recent experimental observations offers a consensus on the direct transcriptional function of Myc: when overexpressed, Myc broadly engages the established euchromatic cis-regulatory landscape of the cell, where the factor generally amplifies transcription. The level of Myc binding at target genes and the transcriptional output are differentially modulated by additional regulators, including Miz1. Targeting Myc oncogenic activity will require an understanding of whether amplification promotes tumorigenesis and the consequences of amplification in tumors adapted to oncogenic Myc.

Indexed as

AnimalsCell Transformation, NeoplasticDrosophilaGene Expression Regulation, NeoplasticGenes, mycHumansKruppel-Like Transcription FactorsNeoplasmsKruppel-Like Transcription FactorsZBTB17 protein, humancancerMyctranscription

Identifiers

PMID25475704
PMCPMC4380620
OpenAlexW2044561975

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.